Rasio utang jangka cendhak marang ekuitas: Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals (AMLX) faces liquidity threats due to a limited drug portfolio and uncertainty regarding insurance reimbursements. R&D is currently undergoing a radical transformation following the failure of its primary product, focusing instead on the discovery of new molecules. This price chart reflects a metric at 0.00. Amylyx Pharmaceuticals (AMLX) aims to lead the dementia therapy segment by developing agents to protect brain cells from degradation.
Rincian analitis perusahaan Amylyx Pharmaceuticals
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Amylyx Pharmaceuticals|AMLX - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Amylyx Pharmaceuticals, Inc.|AMLX - Gunggung utang perusahaan|Utang marang nilai buku Amylyx Pharmaceuticals Inc|AMLX - Utang jangka dawa|Utang jangka cendhak perusahaan Amylyx Pharmaceuticals|Indikator likuiditas cepet amylyx.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
Analisis fundamental perusahaan:Amylyx AMLX
To implement its strategy for expanding its portfolio of drugs against rare neurological pathologies, Amylyx Pharmaceuticals (AMLX) requires precise liquidity management when acquiring new molecules. By analyzing the dynamics of the ratio between short-term liabilities and equity, the investor assesses the share of short-term obligations within the equity structure, where a decreasing coefficient confirms financial stability, while an increase signals risky leverage for operational scaling.
Pesaing Amylyx Pharmaceuticals (AMLX)
Utang jangka cendhak marang modal BIIB|NBIX - Kewajiban jangka cendhak marang modal|Regencell Bioscience - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal axsome.com AXSM|ACAD - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal denalitherapeutics.com|Utang jangka cendhak marang ekuitas Harmony Biosciences Holdings, Inc. (HRMY)|Rasio utang jangka cendhak marang ekuitas Biohaven Ltd BHVN|Trevi Pharma - Rasio utang jangka cendhak marang ekuitas|Praxis Corp (PRAX) - Kewajiban jangka cendhak marang modal|AVXL - Utang jangka cendhak marang ekuitas|CBLL: Utang jangka cendhak marang ekuitas|PRTA (Prothena Corp) - Rasio utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Alector (ALEC)|Rasio utang jangka cendhak marang ekuitas ANNX|Rasio utang jangka cendhak marang modal OMER (Omeros Corp.)|Rasio utang jangka cendhak marang ekuitas NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Voyager Therapeutics, Inc. VYGR|NMRA (Neumora) - Kewajiban jangka cendhak marang ekuitas|Scilex Holding Co. - Utang jangka cendhak marang modal|Rasio tanggungan utang jangka cendhak marang modal TVGN (Tevogen Bio Inc.)|ACOG: Utang jangka cendhak marang modal|cogrx.com (CGTX) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Inhibikase Therapeutics, Inc.|SAVA: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Assertio Holdings, Inc. (ASRT)|Rasio utang jangka cendhak marang ekuitas coyatherapeutics.com COYA|Utang jangka cendhak marang modal VTGN (Vistagen)|Utang jangka cendhak marang modal Ovid Therapeutics Inc OVID|Acumen Pharmaceuticals, Inc. - Utang jangka cendhak marang modal|CervoMed, Inc. (CRVO) - Rasio utang jangka cendhak marang ekuitas|ATHE: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Clene (CLNN)|Rasio utang jangka cendhak marang ekuitas PEPG|Utang jangka cendhak marang modal jupiterneurosciences.com|Rasio utang jangka cendhak marang ekuitas RLMD (Relmada Therapeutics, Inc.)|Rasio silihan jangka cendhak marang modal ANVS|Utang jangka cendhak marang modal GRCE (Grace Therapeutics)|Koefisien utang jangka cendhak marang modal Firefly Neuro (AIFF)|ANEW Medical, Inc. - Utang jangka cendhak marang modal|NeuroSense Therapeutics (NRSN) - Rasio utang jangka cendhak marang ekuitas|RVPH: Utang jangka cendhak marang modal|MetaVia (MTVA) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas NeurAxis, Inc|Utang jangka cendhak marang ekuitas HSDT|Utang jangka cendhak marang ekuitas Passage Bio, Inc. (PASG)|Koefisien utang jangka cendhak marang modal bionomics.com.au|Utang jangka cendhak marang modal NERV (Minerva Neurosciences, Inc.)|Utang jangka cendhak marang modal Athira Pharma Inc ATHA|ADXN - Utang jangka cendhak marang ekuitas|Alzamend Neuro, Inc. (ALZN) - Rasio utang jangka cendhak marang ekuitas|cyclerion.com (CYCN) - Utang jangka cendhak marang ekuitas|PTIX (Protagenic Therapeutics, Inc.) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang ekuitas KTTA|Rasio utang jangka cendhak marang modal CRGT (Cortigent Medical)|Utang jangka cendhak marang ekuitas Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Rasio utang jangka cendhak marang modal|Utang jangka cendhak marang modal CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Kewajiban jangka cendhak marang modal|ELYM: Rasio utang jangka cendhak marang ekuitas|ITCI - Utang jangka cendhak marang modal|Longboard Pharma (LBPH) - Utang jangka cendhak marang ekuitas|Marinus Pharma - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas NKGen Biotech, Inc.|Kewajiban jangka cendhak marang modal neurobopharma.com NRBO|Utang jangka cendhak marang modal SAGE|Utang jangka cendhak marang modal Synaptogenix Inc. (SNPX)|Utang jangka cendhak marang ekuitas Trevena, Inc TRVN|VIGL - Rasio utang jangka cendhak marang ekuitas|WENA: Rasio utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal cerevel.com